Data Sheet (Cat.No.T15244)

TargetMol

Ertugliflozin L-pyroglutamic acid

Chemical Properties



CAS No. : 1210344-83-4

Formula: C27H32ClNO10

Molecular Weight: 566

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM, suitable for studies on the treatment of type 2 diabetes mellitus.
Targets(IC50)	SGLT
In vitro	Ertugliflozin L-pyroglutamic acid demonstrated >2000-fold selectivity for SGLT2 over SGLT[2].
In vivo	The oral administration of Ertugliflozin L-pyroglutamic to rats acid showed concentration-dependent glucosuria[2].

Solubility Information

Solubility	DMSO: 125 mg/mL (220.85 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (7.07 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7668 mL	8.8339 mL	17.6678 mL
5 mM	0.3534 mL	1.7668 mL	3.5336 mL
10 mM	0.1767 mL	0.8834 mL	1.7668 mL
50 mM	0.0353 mL	0.1767 mL	0.3534 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013 Feb;41(2):445-56.
Kalgutkar AS, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011 Sep;39(9):1609-19.
Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60.